BevCanna Enterprises

ILLUMINA NASDAQILMN STOCK QUOTE

https://www.illumina.com/

LATEST NEWS FROM ILLUMINA

Dante Labs Announces Appointment of Global Legal Expert Rachel Haverfield as General Counsel to its Expanding Leadership Team

Illumina Accelerator Invests in Seven Genomics Startups for Third Global Cycle

Dante Labs Announces Expansion of its Finance Team with the Appointment of Andre Nel as Chief Financial Officer, Dalila Rahmani as Chief Accounting Officer, Laura D’Angelo as VP Investor Relations and Omar Elbakshish as Senior Director

Illumina Commits to Net Zero Global Greenhouse Gas Emissions by 2050

Illumina Partners with Merck to Develop and Commercialize Companion Diagnostic and Research Tests for Use in Identifying Specific Cancer Mutations

Illumina To Webcast Upcoming Investor Conference

Illumina Acquires GRAIL to Accelerate Patient Access to Life-Saving Multi-Cancer Early-Detection Test

Illumina Reports Financial Results for Second Quarter of Fiscal Year 2021

Illumina Donates $1 Million in Sequencing Capabilities to Mumbai to Support Sequencing-Based COVID-19 Surveillance in India

Illumina to Webcast Upcoming Investor Conference

Illumina is Committed to Bringing Lifesaving GRAIL Test to People Globally as European Review Process Enters Second Phase

Dante Labs appoints Illumina acclaimed COO Bob Ragusa as Board Member to support the execution of its global integrated precision medicine strategy

Illumina to Announce Second Quarter 2021 Financial Results on Thursday, August 5, 2021

DNA Data Storage Alliance Publishes First White Paper, Launches Website

Illumina Supports Nationwide Program across Belgium to Assess Whole Genome Sequencing for Developmental Disorders Diagnosis

Illumina To Webcast Upcoming Investor Conference

Illumina Appoints Susan Tousi as Chief Commercial Officer and Dr. Alex Aravanis as Chief Technology Officer, Head of Research and Product Development

Myriad Genetics Delivers 12% Sequential Revenue Growth in March 2021 Quarter, Company Executes on Strategic Transformation Initiatives

Illumina To Webcast Upcoming Investor Conference

Illumina Files Action for Annulment of European Commission’s Decision Asserting Jurisdiction to Review GRAIL Acquisition

Illumina to Donate US $60 Million in Sequencing Capabilities to Establish a Global Pathogen Genomics Initiative

Illumina Reports Financial Results for First Quarter of Fiscal Year 2021

Illumina and Kartos Therapeutics Announce New Oncology Partnership to Develop an NGS-Based TP53 Companion Diagnostic

Biotech Veterans Troy Cox, Susannah Gray and Karen McGinnis Join Biosplice Therapeutics Board of Directors

Illumina Remains Committed to GRAIL Acquisition to Accelerate Access to Breakthrough Multi-Cancer Early Detection Blood Test

Illumina Announces Preliminary Revenue for First Quarter Fiscal Year 2021

Illumina Committed to Pursuing GRAIL Acquisition to Accelerate Access to Breakthrough Multi-Cancer Early Detection Blood Test

Illumina Announces Board Changes

Iridia Raises $24 Million in Series B Funding

Illumina and R-Pharm Secure Registration for Two Complete IVD Sequencing Platforms in Russia

Myriad Genetics Joins Forces with Intermountain Precision Genomics for a Comprehensive Offering of Germline and Somatic Tumor Testing Services

Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2020

Illumina to Webcast Upcoming Investor Conference Presentations

Illumina Accelerator Invests in Nine Genomics Startups for Second Global Cycle

Illumina Supports National Program to Evaluate Potential of Comprehensive Genomic Profiling in Late Stage Cancer Real-World Setting Across Belgium

Illumina and Sequoia Capital China Partner to Launch Genomics Incubator in China

Illumina to Announce Fourth Quarter & Full Year 2020 Financial Results on Thursday, February 11, 2021